


POSTER

A Feasibility Study Investigating a Topical Preparation as Novel Adjunct Treatment for the Symptomatic Management of Vulvovaginal Skin Conditions

Dr. Philip Hall, Gynaecologist, MBBS MRMed, FRANZCOG, FRCOG, FACRRM
Pelvic Medicine Centre, St Andrew's War Memorial Hospital Spring Hill Brisbane Australia



INTRODUCTION



These vulvovaginal conditions cause significant **discomfort** and **negatively** impact **quality of life**.
Current **standard treatments** (corticosteroids and hormone therapy) often results in **side effects**, emphasizing the need for alternative therapies.

This study aims to assess the effects of a **novel topical gel** on symptomatic management of vulvovaginal conditions. Properties of the gel:

- **Enhance hydration** and **reduce inflammation**
- **Alleviate symptoms** and **improve patient outcomes** in a non-hormonal way

METHODS

Study design:

- Single-arm
- Feasibility
- Open-label

Study participants:

- 52 women
- Product applied twice daily

Duration of the study:

6 months with optional extension for up to 2 years.

Outcome measures:

- Patient-reported symptom scored (10-point Likert scale)
- Clinical assessment of disease severity
- Evaluation of adverse events and treatment compliance

Diagnosis

■ Lichen Sclerosus
■ Lichen Simplex Chronicus
■ Genitourinary Syndrome of Menopause

Data analysis:

Non-parametric statistical methods to assess symptom changes over time.

RESULTS




Figure 1: Severity of the Symptoms: Patients rated symptom severity on a 10-point scale ranging from 0=normal to 10=worst possible at each visit.




Figure 2: Improvement of Clinical Signs: Investigator assessed clinical signs on a 10-point scale ranging from 0=normal to 10=worst possible at each visit.




Figure 3: Improvement of all Clinical Signs aggregated > Investigator assessed clinical signs on a 10-point scale ranging from 0=normal to 10=worst possible at each visit.

Over **90% treatment adherence** after 1 year

No adverse events related to the gel were reported throughout the study

StrataMGT has **no side effects**, unlike corticosteroids and estrogen therapy, which carry higher risks

DISCUSSION



- These findings suggest:
- The gel could be a **valuable adjunct therapy** for managing **chronic vulvovaginal conditions**
 - Particularly beneficial for patients who experience **side effects** or **inadequate relief** from standard therapies

- Limitations of the study:
- **Larger, controlled** sample needed to confirm these results
 - Lack of **validated** scales
 - Potential **bias** in outcome assessment
 - **Unequal** patient **samples** across different indications